To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration / Michelsen, B., Lindström, U., Codreanu, C., Ciurea, A., Zavada, J., Loft, A.G., Pombo-Suarez, M., Onen, F., Kvien, T.K., Rotar, Z., Santos, M.J., Iannone, F., Hokkanen, A., Gudbjornsson, B., Askling, J., Ionescu, R., Nissen, M.J., Pavelka, K., Sanchez-Piedra, C., Akar, S., et al.. - In: RMD OPEN. - ISSN 2056-5933. - 6:3(2020), pp. e001280-e001280. [10.1136/rmdopen-2020-001280]
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
Sebastiani, Marco;
2020
Abstract
To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2020 michelsen Drug retention.pdf
Open access
Descrizione: Main document
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
